Canaccord analyst Whitney Ijem lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $6 from $18 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report was straightforward, with the more notable news coming earlier in December with the announcement of positive clinical data from cohort 1 of TN-201’s Ph1b/2 (MyPeak-1) for the treatment of MYBPC3-associated HCM.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Buy Rating for Tenaya Therapeutics: Strong Clinical Progress and Financial Stability
- Biotech Alert: Searches spiking for these stocks today
- Tenaya Therapeutics price target lowered to $5 from $15 at Morgan Stanley
- Tenaya Therapeutics Advances Gene Therapy Pipeline
- Tenaya Therapeutics price target lowered to $9 from $18 at Chardan